Real-World Insights on Metabolic Dysfunction-Associated Steatohepatitis: Evaluating Clinical Impact, Disease Progression, and Non-Invasive Risk Assessment - Takeaways - MDSpire

Real-World Insights on Metabolic Dysfunction-Associated Steatohepatitis: Evaluating Clinical Impact, Disease Progression, and Non-Invasive Risk Assessment

  • By

  • Claudio Sartini

  • Ronald Herrera

  • Faizan Mazhar

  • Zuleika Aponte Torres

  • Mireia Raluy

  • Mark Yates

  • Alia Yousif

  • Ramy Younes

  • Jörn M. Schattenberg

  • March 26, 2026

  • 0 min

Share

  • 1

    Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases risks of liver complications and cardiovascular disease.

  • 2

    Non-CV comorbidities in MASH patients, such as cancer and psychiatric disorders, are understudied, highlighting critical gaps in understanding the disease.

  • 3

    Current guidelines recommend non-invasive tests (NITs) like FIB-4 for risk stratification, but real-world studies on their effectiveness are limited.

  • 4

    This study utilizes a large US cohort to assess the clinical burden of MASH, focusing on comorbidities, mortality, and the role of NITs.

  • 5

    Patients were classified by cirrhosis status at MASH diagnosis, which is crucial for understanding disease progression and treatment strategies.

Original Source(s)

Related Content